SNPMiner Trials (Home Page)
Report for Clinical Trial NCT02201602
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study
Gliclazide has greater glucose lowering efficacy than glibenclamide among type 2 diabetes mellitus patients with minor haplotype (K23/A1369) at the KCNJ11/ABCC gene locations.
NCT02201602 Diabetes
2 Interventions
Name: Gliclazide
Name: Glibenclamide
Primary Outcomes
Measure: Mean blood glucose level Time: 6 daysSecondary Outcomes
Description: Glycemic variability will be assessed using the EasyGV software (http://www.phc.ox.ac.uk/research/diabetes/software/easygv/) which is capable of calculating 10 different measures of glycemic variability from continuous glucose monitoring data, such as Standard Deviation (SD) and M-value, mean amplitude of glycemic excursions (MAGE).
Measure: Glycemic variability Time: 6 daysPurpose: Treatment
Allocation: Randomized
Crossover Assignment
There are 2 SNPs
SNPs
1 rs5219
Interestingly, the KCNJ11 E23K (rs5219) variant was shown to confer susceptibility to T2DM and the ABCC8 S1369A (rs757110) variant was found to be in complete linkage disequilibrium with it i.e. inherited together as a genetic block (haplotype).
2 rs757110
Interestingly, the KCNJ11 E23K (rs5219) variant was shown to confer susceptibility to T2DM and the ABCC8 S1369A (rs757110) variant was found to be in complete linkage disequilibrium with it i.e. inherited together as a genetic block (haplotype).